Lisata Therapeutics Inc LSTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
-
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
-
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
-
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry — LSTA, FSHP, BWIN, and ACVA
-
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
-
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
-
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.01–1.07
- 52-Week Range
- $0.96–5.07
- Bid/Ask
- $1.00 / $1.28
- Shares Outstanding
- 10.80M
- Market Cap
- $11.34M
- Volume/Avg
- 45,570 / 300,474
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 92.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.lisata.com
Valuation
|
Metric
|
LSTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.15 |
Price/Sales | 92.69 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LSTA
|
|---|---|
Quick Ratio | 3.50 |
Current Ratio | 3.69 |
Interest Coverage | — |
Quick Ratio
LSTA
Profitability
|
Metric
|
LSTA
|
|---|---|
Return on Assets (Normalized) | −75.84% |
Return on Equity (Normalized) | −93.98% |
Return on Invested Capital (Normalized) | −95.59% |
Return on Assets
LSTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sFqF<RP | LOCK|@xfCv | $133B | |||
| Moderna Inc
MRNA
| LOCK|KMvK#&@ | LOCK|NJs | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^^jMDJ | LOCK|#L<d^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|@j!SDF | LOCK|NJ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H%#lv^ | LOCK|J# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vVtm!% | LOCK|@@wR | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<CG^NNtr | LOCK|gxS^ | $28B | |||
| Incyte Corp
INCY
| LOCK|fkN$w# | LOCK|d<? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%!&D#< | LOCK|<K | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Vb<Hfny | LOCK|>$@ | $14B |
United States